Alteplase at 0.6 mg/kg body weight produces comparable outcomes to the standard 0.9 mg/kg dose in Korean patients with ischaemic stroke, a recent study reveals. Use of low-dose alteplase is common in East Asia, owing to concerns over the risk of cerebral haemorrhage, but few studies have compared it with the standard dose. Over a 6-year period in the Republic of Korea, the low dose was given to ∼30% of 1,526 patients with ischaemic stroke. No differences were seen between the doses in the rates of haemorrhagic conversion or in modified Rankin Scale scores at 3 months. The low dose was also associated with reduced mortality.